.css-1xsl8rf{width:100%;display:-webkit-box;display:-webkit-flex;display:-ms-flexbox;display:flex;-webkit-align-items:center;-webkit-box-align:center;-ms-flex-align:center;align-items:center;position:relative;overflow:hidden;background:var(--alert-bg);-webkit-padding-start:var(--chakra-space-4);padding-inline-start:var(--chakra-space-4);-webkit-padding-end:var(--chakra-space-4);padding-inline-end:var(--chakra-space-4);padding-top:var(--chakra-space-1);padding-bottom:var(--chakra-space-1);--alert-fg:var(--chakra-colors-orange-600);--alert-bg:var(--chakra-colors-orange-100);font-weight:var(--chakra-fontWeights-semibold);padding-left:var(--chakra-space-4);}.chakra-ui-dark .css-1xsl8rf:not([data-theme]),[data-theme=dark] .css-1xsl8rf:not([data-theme]),.css-1xsl8rf[data-theme=dark]{--alert-fg:var(--chakra-colors-orange-200);--alert-bg:rgba(251, 211, 141, 0.16);}@media screen and (min-width: 48em){.css-1xsl8rf{padding-left:var(--chakra-space-8);}}Bitte aktivieren Sie Javascript um alle Funktionen nutzen zu können und ihre Nutzererfahrung zu verbessern.

Karen Carr

Vortrag

09.12.2022
15:45 – 15:50 3 Min. 2 Min.
ePoster
P105
Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12- and 52-Week Phase 3 Trials
Migraine
09.12.2022
15:50 – 15:55 3 Min. 2 Min.
ePoster
P106
Post-hoc Analysis Evaluating Safety of Atogepant in ADVANCE & Open-Label Extension Participants with Cardiovascular Risk Factors
Migraine
09.12.2022
16:10 – 16:15 3 Min. 2 Min.
ePoster
P110
Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial
Migraine
09.12.2022
16:55 – 17:00 3 Min. 2 Min.
ePoster
P120
Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis
Migraine

Weitere Beteiligungen

09.12.2022
15:45 – 15:50 3 Min. 2 Min.
ePoster
P105
Sustained Response to Atogepant in Individuals with Episodic Migraine: Post Hoc Analyses of 12- and 52-Week Phase 3 Trials
Migraine
09.12.2022
15:50 – 15:55 3 Min. 2 Min.
ePoster
P106
Post-hoc Analysis Evaluating Safety of Atogepant in ADVANCE & Open-Label Extension Participants with Cardiovascular Risk Factors
Migraine
09.12.2022
16:10 – 16:15 3 Min. 2 Min.
ePoster
P110
Subsequent Response to Atogepant in Individuals with Episodic Migraine after an Initial Inadequate Response: Post Hoc Analysis of a 12-week Phase 3 Trial
Migraine
09.12.2022
16:55 – 17:00 3 Min. 2 Min.
ePoster
P120
Monthly Migraine Days, Acute Medication Use Days, and Migraine-Specific Quality of Life in Responders to Atogepant: A Post Hoc Analysis
Migraine